New combo therapy for tough lung cancer cases shows promise in early trial
NCT ID NCT04549428
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tested a combination of the immunotherapy drug atezolizumab and a single low dose of radiation in 12 adults with advanced lung cancer (stage IV) whose disease had worsened after both chemotherapy and another type of immunotherapy. The goal was to see if this approach could shrink tumors or slow cancer growth. The trial was stopped early, and results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cantonal Hospital of Graubünden (KSGR)
Chur, 7000, Switzerland
-
Geneva University Hospitals (HUG)
Geneva, 1205, Switzerland
-
Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
Conditions
Explore the condition pages connected to this study.